Medullary thyroid cancer makes up roughly 2% of all thyroid cancers in the United States but causes approximately 8% of thyroid cancer deaths, according to a StatPearls review available through the NIH National Library of Medicine. This higher death rate points to a key clinical challenge: MTC does not respond to radioactive iodine, so tracking tumor markers after surgery matters more. The main tool is serum calcitonin. How fast calcitonin changes matters more than any single reading.
Why Calcitonin Velocity Is the Key Signal
A single calcitonin measurement shows how much tumor-secreting cell mass is likely present. A series of measurements over time shows something more important: how fast that mass is growing. Doctors use calcitonin doubling time (Ct-DT) to measure velocity, and research shows it works better than single values as a predictor of outcomes.
Research on how well tumor marker doubling times predict outcomes in MTC, available through the NIH PMC repository, found major survival differences across Ct-DT categories. Patients with Ct-DT under 6 months had 25% five-year survival and 8% ten-year survival. When Ct-DT was longer than 2 years, every patient was still alive at follow-up's end. This is not a small difference. It is why Ct-DT drives clinical decisions in MTC more than most other thyroid cancer markers.
A review in Nature Reviews Endocrinology confirmed that both calcitonin and carcinoembryonic antigen (CEA) doubling times predict disease progression, and velocity measurements give doctors information that standard imaging alone cannot.
CEA as a Parallel Velocity Signal
Doctors track CEA alongside calcitonin in MTC surveillance. When CEA velocity speeds up while calcitonin slows, or vice versa, the gap might suggest the tumor is changing. Tracking both markers as trends, not as single values, lets doctors spot disease changes between imaging appointments.
Research published in ASCO JCO Precision Oncology looked at changes in serum calcitonin in MTC across long surveillance periods. Calcitonin levels can go up or down, proving that how fast they change matters more than any single result.
What the Standard Surveillance Schedule Requires
The American Thyroid Association guidelines for medullary thyroid carcinoma say patients with detectable calcitonin after surgery should get calcitonin and CEA measurements at 2-3 months after thyroidectomy, then twice a year for two years, then yearly. Doctors do cervical ultrasound yearly for the first three years, then every two years through year ten.
The schedule makes sense. The real challenge is running it in a way that shows trends, not just single numbers at each review.
Where Manual Tracking Breaks Down
Doctors managing MTC patients hit a data problem between appointments. Lab results arrive from outside labs, often as PDFs, and the EHR stores the number but doesn't automatically calculate Ct-DT. To find velocity, a doctor must dig through old results, check the dates, and do the math - usually in a few minutes between patients.
Different EHR systems make the problem worse. As Healthcare IT News has reported, when records spread across multiple systems, care teams have to manually piece together patient history during the visit itself - and they might miss parts of it.
Consider a real example. A patient's calcitonin rises from 40 pg/mL at a 3-month post-surgery check to 310 pg/mL fifteen months later. Anyone looking at the full series sees the trend. But most EHRs show each result separately, not as part of a trend. If old results are tucked in a different note, doctors might not see the pattern until the fourth or fifth reading. By then, months have gone by and the chance to act early is lost.
The Long-Horizon Problem in Hereditary MTC
Sporadic MTC already needs years of watching. Hereditary MTC - connected to MEN2A and MEN2B syndromes - often needs a decade or more. Data from 2000-2020, published in the NIH PMC repository, show that MTC deaths rose 3.46% per year. Clinics now manage more patients for longer periods than a decade ago.
Over ten years or more, Ct-DT trajectories change. A patient's doubling time can drop during active disease and rise during stable disease. Relying on a single result without the full trend misses the context. Tracking by hand - in a spreadsheet or EHR field - gets messy as staff leave, volume grows, and patients change providers.
How Rucja Addresses the Gap
Rucja's Lab Intelligence module tracks serial biomarkers, including MTC calcitonin and CEA. When a result comes in, the system adds it to the patient's prior results and calculates the new doubling time. Doctors see Ct-DT and the raw value together on the patient timeline.
Clinics can set alerts at any level they choose. An MTC program can set a Ct-DT alert at 6 months, 12 months, or whatever the team picks. When a new result drops the Ct-DT below that threshold, the doctor gets a notification right away, not during the appointment.
The system tracks both markers at the same time. A doctor looking at a patient's timeline can see whether the two markers move together or apart - a gap that is hard to spot when doctors look at one result at a time.
For clinics managing hereditary MTC patients across multiple providers, the system keeps one complete record for the whole surveillance period. This approach works wherever tracking biomarker speed is the main way to watch disease. Similar issues appear in Chromogranin A monitoring in GEP-NET surveillance and AFP velocity tracking in hepatocellular carcinoma surveillance. The same challenge shows up in differentiated thyroid cancer, covered in our article on TSH suppression monitoring in thyroid cancer follow-up.
What This Means for Clinic Operations
For administrators looking at oncology software, one question says a lot: does the platform automatically calculate calcitonin doubling time from lab results? If not, clinic staff have to do it by hand at every visit.
The result is not a sudden crash but slow, hidden wear - a trend that goes unseen for one cycle, then another, as the patient's calcitonin shifts from stable to concerning. In a disease where a 6-month Ct-DT versus a 24-month Ct-DT directly affects how long patients survive, this wear matters.
Rucja doesn't diagnose or recommend treatment. It shows doctors a calculated view of a trend that's already in the data - one that most EHRs need lots of manual work to show.
Demos take 30 minutes. We show you how Lab Intelligence tracks serial calcitonin and CEA velocity using your clinic's actual patient data. Book a demo.